ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
96,860.63
-0.04%
S&P 500
5,868.55
-0.22%
Dow Jones
42,392.27
-0.36%
US Dollar vs Yen
157.3685
-0.23%
Brent Oil
75.855
0.00%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Revance Therapeutics Inc (RVNC)

  7. Revance Therapeutics Inc (RVNC) ニュース

RVNC

Revance Therapeutics (RVNC)

Revance Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:RVNC
日付受信時刻ニュースソース見出しコード企業名
2025/01/0306 : 45Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
2025/01/0306 : 36Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
2024/12/1923 : 00Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
2024/12/1222 : 01Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:RVNCRevance Therapeutics Inc
2024/12/1222 : 00PR Newswire (US)Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per shareNASDAQ:RVNCRevance Therapeutics Inc
2024/12/1221 : 15Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:RVNCRevance Therapeutics Inc
2024/12/1220 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/12/1007 : 16Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:RVNCRevance Therapeutics Inc
2024/12/0923 : 24Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:RVNCRevance Therapeutics Inc
2024/12/0923 : 17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/12/0922 : 30PR Newswire (US)Crown Laboratories and Revance Enter into Amended and Restated Merger AgreementNASDAQ:RVNCRevance Therapeutics Inc
2024/12/0922 : 30Business WireCrown Laboratories and Revance Enter into Amended and Restated Merger AgreementNASDAQ:RVNCRevance Therapeutics Inc
2024/12/0606 : 23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/12/0322 : 27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/11/2920 : 02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/11/2620 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/11/2006 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
2024/11/2006 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/11/0806 : 12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/11/0806 : 05Business WireRevance Reports Third Quarter 2024 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
2024/11/0122 : 24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/10/1822 : 29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/10/0420 : 32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/09/2722 : 17PR Newswire (US)Kuehn Law Encourages RVNC, RFL, BTTR, and ARC Investors to Contact Law FirmNASDAQ:RVNCRevance Therapeutics Inc
2024/09/2320 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/09/1706 : 01Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RVNCRevance Therapeutics Inc
2024/09/1005 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
2024/09/0606 : 27Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:RVNCRevance Therapeutics Inc
2024/09/0605 : 45Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:RVNCRevance Therapeutics Inc
2024/08/1322 : 29Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:RVNCRevance Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RVNC

最近閲覧した銘柄

NYSE
DIS
Walt Disney
COIN
DOGEUSD
Dogecoin
NYSE
MCD
McDonalds
NYSE
NKE
Nike
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
SOLUSD
Solana
CCOM
US100
US Tech 100
AMEX
SPY
SPDR S&P 500
NYSE
CVX
Chevron
NYSE
MRK
Merck
NASDAQ
MSFT
Microsoft
COIN
XRPUSD
Ripple
NASDAQ
NVDA
NVIDIA
FX
USDEUR
US Dollar vs Euro
USOTC
ADDYY
Adidas (QX)
USOTC
BNPQY
BNP Paribas (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有